Perspective Therapeutics (CATX) Gross Margin (2010 - 2023)

Perspective Therapeutics (CATX) posted Gross Margin of 20.6% for Q4 2023, down 39.0% sequentially from 33.78% in Q3 2023.

Perspective Therapeutics (CATX) Gross Margin (2010 - 2023) Analysis & Trends

Perspective Therapeutics has reported Gross Margin for 14 years, with the latest figure at 20.6% in Q4 2023.

Quarterly Gross Margin changed N/A year-over-year to 20.6% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 54.73% (changed N/A YoY) and the FY2023 annual result came in at 32.29%, changed N/A from the prior year.
Gross Margin retreated to 20.6% in Q4 2023 per CATX's latest filing, from 33.78% in the prior quarter.
Over five years, Gross Margin peaked at 59.24% in Q1 2020 and troughed at 16.53% in Q2 2023.
A 5-year average of 42.91% and a median of 45.69% in 2019 frame the typical range for Gross Margin.
The sharpest annual moves came in 2019 and 2023: Gross Margin jumped 1984 bps in 2019, then slumped 2718 bps in 2023.
Over 5 years, Gross Margin stood at 50.36% in 2019, then declined by 2 bps to 49.47% in 2020, then slipped by 12 bps to 43.32% in 2021, then dropped by 10 bps to 38.99% in 2022, then slumped by 47 bps to 20.6% in 2023.
According to Business Quant data, Gross Margin over the past three periods registered 20.6%, 33.78%, and 16.53% for Q4 2023, Q3 2023, and Q2 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Abbott Laboratories	200.19 Bn	194.59 Bn	7.27 Bn	57.71%
2	Stryker	129.95 Bn	126.47 Bn	4.50 Bn	68.27%
3	Medtronic	120.06 Bn	110.84 Bn	6.41 Bn	65.35%
4	Boston Scientific	74.14 Bn	73.60 Bn	3.85 Bn	70.71%
5	Edwards Lifesciences	52.74 Bn	48.49 Bn	1.35 Bn	77.46%
6	Dexcom	34.60 Bn	32.65 Bn	830.00 Mn	63.44%
7	GE HealthCare Technologies	34.20 Bn	32.10 Bn	2.18 Bn	41.17%
8	Koninklijke Philips	26.46 Bn	23.13 Bn	4.55 Bn	47.38%
9	Steris	23.25 Bn	22.77 Bn	684.20 Mn	45.84%
10	Perspective Therapeutics	388.50 Mn	388.50 Mn	-	-

Download Data